Microenvironment-Related Biomarkers and Novel Targets in Classical Hodgkin’s Lymphoma

References

• Siegel R , MaJ, ZouZ, JemalA. Cancer statistics, 2014. CA Cancer J. Clin.64(1), 9–29 (2014).
   PubMed Web of Science ®Google Scholar
• Santoro A , BonadonnaG, ValagussaPet al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J. Clin. Oncol.5(1), 27–37 (1987).
   PubMed Web of Science ®Google Scholar
• Engert A , PlutschowA, EichHTet al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N. Engl. J. Med.363(7), 640–652 (2010).
   PubMed Web of Science ®Google Scholar
• Canellos GP , RosenbergSA, FriedbergJW, ListerTA, DevitaVT. Treatment of Hodgkin lymphoma: a 50-year perspective. J. Clin. Oncol.32(3), 163–168 (2014).
   PubMed Web of Science ®Google Scholar
• Linch DC , WinfieldD, GoldstoneAHet al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet341(8852), 1051–1054 (1993).
   PubMed Web of Science ®Google Scholar
• Brice P , DivineM, SimonDet al. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin’s disease (HD). SFGM/GELA Study Group. Ann. Oncol.10(12), 1485–1488 (1999).
   PubMed Web of Science ®Google Scholar
• Moskowitz CH , NimerSD, ZelenetzADet al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood97(3), 616–623 (2001).
   PubMed Web of Science ®Google Scholar
• Schmitz N , PfistnerB, SextroMet al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet359(9323), 2065–2071 (2002).
   PubMed Web of Science ®Google Scholar
• Moskowitz CH , KewalramaniT, NimerSD, GonzalezM, ZelenetzAD, YahalomJ. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br. J. Hematol.124(5), 645–652 (2004).
   PubMed Web of Science ®Google Scholar
• Majhail NS , WeisdorfDJ, DeforTEet al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol. Blood Marrow Transplant.12(10), 1065–1072 (2006).
   PubMed Web of Science ®Google Scholar
• Gopal AK , MetcalfeTL, GooleyTAet al. High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience. Cancer113(6), 1344–1350 (2008).
   PubMed Web of Science ®Google Scholar
• Viviani S , Di NicolaM, BonfanteVet al. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leukemia Lymphoma51(7), 1251–1259 (2010).
   PubMed Web of Science ®Google Scholar
• Younes A . Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am. Soc. Hematol. Educ. Program2009, 507–519 (2009).
   Google Scholar
• Canellos GP . Brentuximab vedotin and panobinostat: new drugs for Hodgkin’s lymphoma – can they make one of medical oncology’s chemotherapy success stories more successful?J. Clin. Oncol.30(18), 2171–2172 (2012).
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ , PeralesM-A, KewalramaniTet al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br. J. Hematol.146(2), 158–163 (2009).
   PubMed Web of Science ®Google Scholar
• Martinez C , CanalsC, SarinaBet al. Identification of prognostic factors predicting outcome in Hodgkin’s lymphoma patients relapsing after autologous stem cell transplantation. Ann. Oncol.24(9), 2430–2434 (2013).
   PubMed Web of Science ®Google Scholar
• Arai S , FanaleM, DevosSet al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leukemia Lymphoma54(11), 2531–2533 (2013).
   PubMed Web of Science ®Google Scholar
• Crump M . Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology Am. Soc. Hematol. Educ. Program2008, 326–333 (2008).
   Google Scholar
• Younes A . Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat. Rev. Clin. Oncol.8(2), 85–96 (2011).
   PubMed Web of Science ®Google Scholar
• Younes A , BartlettNL, LeonardJPet al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med.363(19), 1812–1821 (2010).
   PubMed Web of Science ®Google Scholar
• Younes A , GopalAK, SmithSEet al. Results of a pivotal Phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol.30(18), 2183–2189 (2012).
   PubMed Web of Science ®Google Scholar
• Carlo-Stella C , RicciF, DaltoSet al. Brentuximab Vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient programme at four Italian centers. Oncologist (2014) ( In Press).
   Web of Science ®Google Scholar
• Ansell SM , LesokhinAM, BorrelloIet al. PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med.372(4), 311–319 (2014).
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ , HamlinPAJr, PeralesMAet al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J. Clin. Oncol.31(4), 456–460 (2013).
   PubMed Web of Science ®Google Scholar
• Anastasia A , Carlo-StellaC, CorradiniPet al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br. J. Hematol.166(1), 140–142 (2014).
   PubMed Web of Science ®Google Scholar
• Sarina B , CastagnaL, FarinaLet al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood115(18), 3671–3677 (2010).
   PubMed Web of Science ®Google Scholar
• Sureda A , RobinsonS, CanalsCet al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol.26(3), 455–462 (2008).
   PubMed Web of Science ®Google Scholar
• Corradini P , SarinaB, FarinaL. Allogeneic transplantation for Hodgkin’s lymphoma. Br. J. Hematol.152(3), 261–272 (2011).
   PubMed Web of Science ®Google Scholar
• Kuppers R . The biology of Hodgkin’s lymphoma. Nat. Rev. Cancer9(1), 15–27 (2009).
   PubMed Web of Science ®Google Scholar
• Aldinucci D , LorenzonD, OlivoK, RapanaB, GatteiV. Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed–Sternberg cells. Leukemia Lymphoma45(9), 1731–1739 (2004).
   PubMed Web of Science ®Google Scholar
• Falini B , FizzottiM, PucciariniAet al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood95(6), 2084–2092 (2000).
   PubMed Web of Science ®Google Scholar
• Aldinucci D , GloghiniA, PintoA, De FilippiR, CarboneA. The classical Hodgkin’s lymphoma microenvironment and its role in promoting tumour growth and immune escape. J. Pathol.221(3), 248–263 (2010).
   PubMed Web of Science ®Google Scholar
• Steidl C , ConnorsJM, GascoyneRD. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J. Clin. Oncol.29(14), 1812–1826 (2011).
   PubMed Web of Science ®Google Scholar
• Ma Y , VisserL, BlokzijlTet al. The CD4+CD26- T-cell population in classical Hodgkin’s lymphoma displays a distinctive regulatory T-cell profile. Lab. Invest.88(5), 482–490 (2008).
   PubMed Web of Science ®Google Scholar
• Maggio EM , Van Den BergA, VisserLet al. Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas. Int. J. Cancer99(5), 665–672 (2002).
   PubMed Web of Science ®Google Scholar
• Fischer M , JuremalmM, OlssonNet al. Expression of CCL5/RANTES by Hodgkin and Reed–Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int. J. Cancer107(2), 197–201 (2003).
   PubMed Web of Science ®Google Scholar
• Van Den Berg A , VisserL, PoppemaS. High expression of the CC chemokine TARC in Reed–Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin’s lymphoma. Am. J. Pathol.154(6), 1685–1691 (1999).
   PubMed Web of Science ®Google Scholar
• Ohshima K , TutiyaT, YamaguchiTet al. Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed–Sternberg (H&RS) cells in Hodgkin disease: relation with expression of CXC and CC chemokines on H&RS cells. Int. J. Cancer98(4), 567–572 (2002).
   PubMed Web of Science ®Google Scholar
• Schreck S , FriebelD, BuettnerMet al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol. Oncol.27(1), 31–39 (2009).
   PubMed Web of Science ®Google Scholar
• Yamamoto R , NishikoriM, KitawakiTet al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood111(6), 3220–3224 (2008).
   PubMed Web of Science ®Google Scholar
• Marshall NA , ChristieLE, MunroLRet al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood103(5), 1755–1762 (2004).
   PubMed Web of Science ®Google Scholar
• Shi L , ChenS, YangL, LiY. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J. Hematol. Oncol.6(1), 74 (2013).
   PubMedGoogle Scholar
• Dukers DF , JasparsLH, VosWet al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein–Barr virus-positive and -negative cases of Hodgkin’s disease. J. Pathol.190(2), 143–149 (2000).
   PubMed Web of Science ®Google Scholar
• Ma Y , VisserL, RoelofsenHet al. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood111(4), 2339–2346 (2008).
   PubMed Web of Science ®Google Scholar
• Truman LA , FordCA, PasikowskaMet al. CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood112(13), 5026–5036 (2008).
   PubMed Web of Science ®Google Scholar
• Leng L , MetzCN, FangYet al. MIF signal transduction initiated by binding to CD74. J. Exp. Med.197(11), 1467–1476 (2003).
   PubMed Web of Science ®Google Scholar
• Stein R , QuZ, CardilloTMet al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood104(12), 3705–3711 (2004).
   PubMed Web of Science ®Google Scholar
• Foss HD , HerbstH, GottsteinS, DemelG, AraujoI, SteinH. Interleukin-8 in Hodgkin’s disease. Preferential expression by reactive cells and association with neutrophil density. Am. J. Pathol.148(4), 1229–1236 (1996).
   PubMed Web of Science ®Google Scholar
• Kapp U , YehWC, PattersonBet al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed–Sternberg cells. J. Exp. Med.189(12), 1939–1946 (1999).
   PubMed Web of Science ®Google Scholar
• Khnykin D , TroenG, BernerJM, DelabieJ. The expression of fibroblast growth factors and their receptors in Hodgkin’s lymphoma. J. Pathol.208(3), 431–438 (2006).
   PubMed Web of Science ®Google Scholar
• Ohshima K , AkaiwaM, UmeshitaR, SuzumiyaJ, IzuharaK, KikuchiM. Interleukin-13 and interleukin-13 receptor in Hodgkin’s disease: possible autocrine mechanism and involvement in fibrosis. Histopathology38(4), 368–375 (2001).
   PubMed Web of Science ®Google Scholar
• Jundt F , AnagnostopoulosI, BommertKet al. Hodgkin/Reed–Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood94(6), 2065–2071 (1999).
   PubMed Web of Science ®Google Scholar
• Foss HD , HerbstH, OelmannEet al. Lymphotoxin, tumour necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed–Sternberg cells of most Hodgkin’s disease cases. Br. J. Hematol.84(4), 627–635 (1993).
   PubMed Web of Science ®Google Scholar
• Xerri L , BirgF, GuigouV, BouabdallahR, Poizot-MartinI, HassounJ. In situ expression of the IL-1-alpha and TNF-alpha genes by Reed–Sternberg cells in Hodgkin’s disease. Int. J. Cancer50(5), 689–693 (1992).
   PubMed Web of Science ®Google Scholar
• Bechtel D , KurthJ, UnkelC, KuppersR. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood106(13), 4345–4350 (2005).
   PubMed Web of Science ®Google Scholar
• Chaganti S , BellAI, PastorNBet al. Epstein–Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes. Blood106(13), 4249–4252 (2005).
   PubMed Web of Science ®Google Scholar
• Mancao C , AltmannM, JungnickelB, HammerschmidtW. Rescue of “crippled” germinal center B cells from apoptosis by Epstein–Barr virus. Blood106(13), 4339–4344 (2005).
   PubMed Web of Science ®Google Scholar
• Marshall NA , CulliganDJ, TigheJ, JohnstonPW, BarkerRN, VickersMA. The relationships between Epstein–Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin’s lymphoma. Exp. Hematol.35(4), 596–604 (2007).
   PubMed Web of Science ®Google Scholar
• Maggio E , Van Den BergA, DiepstraA, KluiverJ, VisserL, PoppemaS. Chemokines, cytokines and their receptors in Hodgkin’s lymphoma cell lines and tissues. Ann. Oncol.13(Suppl. 1), 52–56 (2002).
   PubMed Web of Science ®Google Scholar
• Uchihara JN , KrenskyAM, MatsudaTet al. Transactivation of the CCL5/RANTES gene by Epstein–Barr virus latent membrane protein 1. Int. J. Cancer114(5), 747–755 (2005).
   PubMed Web of Science ®Google Scholar
• Baumforth KR , BirgersdotterA, ReynoldsGMet al. Expression of the Epstein–Barr virus-encoded Epstein–Barr virus nuclear antigen 1 in Hodgkin’s lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am. J. Pathol.173(1), 195–204 (2008).
   PubMed Web of Science ®Google Scholar
• Chetaille B , BertucciF, FinettiPet al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood113(12), 2765–3775 (2009).
   PubMed Web of Science ®Google Scholar
• Skinnider BF , MakTW. The role of cytokines in classical Hodgkin lymphoma. Blood99(12), 4283–4297 (2002).
   PubMed Web of Science ®Google Scholar
• Mathas S , JohrensK, JoosSet al. Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood106(13), 4287–4293 (2005).
   PubMed Web of Science ®Google Scholar
• Schmitz R , HansmannML, BohleVet al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J. Exp. Med.206(5), 981–989 (2009).
   PubMed Web of Science ®Google Scholar
• Emmerich F , TheurichS, HummelMet al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed–Sternberg cells. J. Pathol.201(3), 413–420 (2003).
   PubMed Web of Science ®Google Scholar
• Leonard WJ . Role of Jak kinases and STATs in cytokine signal transduction. Int. J. Hematol.73(3), 271–277 (2001).
   PubMed Web of Science ®Google Scholar
• Karin M , GallagherE. TNFR signaling: ubiquitin-conjugated TRAFfic signals control stop-and-go for MAPK signaling complexes. Immunol. Rev.228(1), 225–240 (2009).
   PubMedGoogle Scholar
• Manning G , WhyteDB, MartinezR, HunterT, SudarsanamS. The protein kinase complement of the human genome. Science298(5600), 1912–1934 (2002).
   PubMed Web of Science ®Google Scholar
• Messineo C , JamersonMH, HunterEet al. Gene expression by single Reed–Sternberg cells: pathways of apoptosis and activation. Blood91(7), 2443–2451 (1998).
   PubMed Web of Science ®Google Scholar
• Fiumara P , SnellV, LiYet al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood98(9), 2784–2790 (2001).
   PubMed Web of Science ®Google Scholar
• Hedvat CV , JaffeES, QinJet al. Macrophage-derived chemokine expression in classical Hodgkin’s lymphoma: application of tissue microarrays. Mod. Pathol.14(12), 1270–1276 (2001).
   PubMed Web of Science ®Google Scholar
• Aldinucci D , LorenzonD, CattaruzzaLet al. Expression of CCR5 receptors on Reed–Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int. J. Cancer122(4), 769–776 (2008).
   PubMed Web of Science ®Google Scholar
• Cattaruzza L , GloghiniA, OlivoKet al. Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed–Sternberg cells: involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin’s lymphoma. Int. J. Cancer125(5), 1092–1101 (2009).
   PubMed Web of Science ®Google Scholar
• Tanijiri T , ShimizuT, UehiraKet al. Hodgkin’s Reed–Sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. J. Leukoc. Biol.82(3), 576–584 (2007).
   PubMed Web of Science ®Google Scholar
• Kadin ME , AgnarssonBA, EllingsworthLR, NewcomSR. Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin’s disease. Am. J. Pathol.136(6), 1209–1214 (1990).
   PubMed Web of Science ®Google Scholar
• Kim LH , EowGI, PehSC, PoppemaS. The role of CD30, CD40 and CD95 in the regulation of proliferation and apoptosis in classical Hodgkin’s lymphoma. Pathology35(5), 428–435 (2003).
   PubMed Web of Science ®Google Scholar
• Gandhi MK , MollG, SmithCet al. Galectin-1 mediated suppression of Epstein–Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood110(4), 1326–1329 (2007).
   PubMed Web of Science ®Google Scholar
• Green MR , MontiS, RodigSJet al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood116(17), 3268–3277 (2010).
   PubMed Web of Science ®Google Scholar
• Diepstra A , Van ImhoffGW, Karim-KosHEet al. HLA class II expression by Hodgkin Reed–Sternberg cells is an independent prognostic factor in classical Hodgkin’s lymphoma. J. Clin. Oncol.25(21), 3101–3108 (2007).
   PubMed Web of Science ®Google Scholar
• Poppema S . Immunobiology and pathophysiology of Hodgkin lymphomas. Hematology Am. Soc. Hematol. Educ. Program2005, 231–238 (2005).
   Google Scholar
• Reichel J , ChadburnA, RubinsteinPGet al. Flow-sorting and exome sequencing reveals the oncogenome of primary Hodgkin and Reed–Sternberg cells. Blood125(7), 1061–1072 (2015).
   PubMed Web of Science ®Google Scholar
• Steidl C , LeeT, ShahSPet al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N. Engl. J. Med.362(10), 875–885 (2010).
   PubMed Web of Science ®Google Scholar
• Klein JL , NguyenTT, Bien-WillnerGAet al. CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. Am. J. Clin. Pathol.141(3), 381–387 (2014).
   PubMed Web of Science ®Google Scholar
• Kamper P , BendixK, Hamilton-DutoitS, HonoreB, NyengaardJR, D’amoreF. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein–Barr virus status in classical Hodgkin’s lymphoma. Haematologica96(2), 269–276 (2011).
   PubMed Web of Science ®Google Scholar
• Harris JA , JainS, RenQ, ZarinehA, LiuC, IbrahimS. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn. Pathol.7, 12 (2012).
   PubMed Web of Science ®Google Scholar
• Azambuja D , NatkunamY, BiasoliIet al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin’s lymphoma. Ann. Oncol.23(3), 736–742 (2012).
   PubMed Web of Science ®Google Scholar
• Van Gorp H , DelputtePL, NauwynckHJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol. Immunol.47(7–8), 1650–1660 (2010).
   PubMed Web of Science ®Google Scholar
• Mantovani A , GermanoG, MarchesiF, LocatelliM, BiswasSK. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur. J. Immunol.41(9), 2522–2525 (2011).
   PubMed Web of Science ®Google Scholar
• Tan KL , ScottDW, HongFet al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood120(16), 3280–3287 (2012).
   PubMed Web of Science ®Google Scholar
• Germano G , FrapolliR, BelgiovineCet al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell23(2), 249–262 (2013).
   PubMed Web of Science ®Google Scholar
• Weihrauch MR , ManzkeO, BeyerMet al. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin’s disease: potential for a prognostic factor. Cancer Res.65(13), 5516–5519 (2005).
   PubMed Web of Science ®Google Scholar
• Plattel WJ , Van Den BergA, VisserLet al. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin’s lymphoma. Haematologica97(3), 410–415 (2012).
   PubMed Web of Science ®Google Scholar
• Sauer M , PlutschowA, JachimowiczRDet al. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am. J. Hematol.88(2), 113–115 (2013).
   PubMed Web of Science ®Google Scholar
• Mestre F , GutierrezA, RamosRet al. Expression of COX-2 on Reed–Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD. Blood119(25), 6072–6079 (2012).
   PubMed Web of Science ®Google Scholar
• Younes A , OkiY, BociekRGet al. Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, Phase 2 trial. Lancet Oncol.12(13), 1222–1228 (2011).
   PubMed Web of Science ®Google Scholar
• Younes A , SuredaA, Ben-YehudaDet al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a Phase II study. J. Clin. Oncol.30(18), 2197–2203 (2012).
   PubMed Web of Science ®Google Scholar
• Johnston PB , InwardsDJ, ColganJPet al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am. J. Hematol.85(5), 320–324 (2010).
   PubMed Web of Science ®Google Scholar
• Guidetti A , Carlo-StellaC, LocatelliSLet al. Phase II study of sorafenib in patients with relapsed or refractory lymphoma. Br. J. Hematol.158(1), 108–119 (2012).
   PubMed Web of Science ®Google Scholar
• Greenwald DR , LiH, LugerSMet al. A Phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404). J. Hematol. Oncol.6, 46 (2013).
   PubMed Web of Science ®Google Scholar
• Guidetti A , Carlo-StellaC, LocatelliSLet al. Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases. Clin. Cancer. Res.20(22), 5641–5651 (2014).
   PubMed Web of Science ®Google Scholar
• Fehniger TA , LarsonS, TrinkausKet al. A Phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood118(19), 5119–5125 (2011).
   PubMed Web of Science ®Google Scholar
• Chen R , PalmerJM, TsaiNCet al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for hodgkin lymphoma. Biol. Blood Marrow Transplant.20(11), 1864–1868 (2014).
   PubMed Web of Science ®Google Scholar
• Gopal AK , RamchandrenR, O’connorOAet al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood120(3), 560–568 (2012).
   PubMed Web of Science ®Google Scholar
• Green MR , RodigS, JuszczynskiPet al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin. Cancer. Res.18(6), 1611–1618 (2012).
   PubMed Web of Science ®Google Scholar
• Locatelli SL , ClerisL, StirparoGGet al. BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi givinostat and sorafenib in Hodgkin lymphoma cell line xenografts. Leukemia28(9), 1861–1871 (2014).
   PubMed Web of Science ®Google Scholar
• Locatelli SL , GiacominiA, GuidettiAet al. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. Leukemia27(8), 1677–1687 (2013).
   PubMed Web of Science ®Google Scholar
• Younes A , ProB, FayadL. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood107(4), 1731–1732 (2006).
   PubMed Web of Science ®Google Scholar
• Younes A , OkiY, MclaughlinPet al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood119(18), 4123–4128 (2012).
   PubMed Web of Science ®Google Scholar
• Kasamon YL , JaceneHA, GockeCDet al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood119(18), 4129–4132 (2012).
   PubMed Web of Science ®Google Scholar
• Smith SM , SchoderH, JohnsonJLet al. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leukemia Lymphoma54(7), 1405–1410 (2013).
   PubMed Web of Science ®Google Scholar